Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

QR Code

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

Introduction: This Phase I study evaluated the safety, tolerability and efficacy of olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). Methods: Eligible patients who had received =1 p...

Full description

Bibliographic Details
Main Authors:	Dent, R., Lindeman, G., Clemons, M., Wildiers, H., Chan, Arlene, McCarthy, N., Singer, C., Lowe, E., Watkins, C., Carmichael, J.
Format:	Journal Article
Published:	2013
Online Access:	http://hdl.handle.net/20.500.11937/14874

Similar Items

PARP inhibitor combinations with Olaparib for synergistic efficacy in Olaparib-resistant triple-negative breast cancer cells
by: Yusoh, Nur Aininie
Published: (2023)

Synergy of ruthenium metallo-intercalator, [Ru(dppz)2(PIP)]2+, with PARP inhibitor Olaparib in non-small cell lung cancer cells
by: Yusoh, Nur Aininie, et al.
Published: (2023)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

Synthesis of small molecules targeting paclitaxel-induced MyD88 expression in triple-negative breast cancer cell lines
by: Khor, Poh Yen, et al.
Published: (2021)

Metallointercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition
by: Yusoh, Nur Aininie, et al.
Published: (2020)

Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
by: Gianni, L., et al.
Published: (2018)

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

Discovery of ruthenium(ii) metallocompound and olaparib synergy for cancer combination therapy
by: Yusoh, Nur Aininie, et al.
Published: (2023)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

The association of ICAM-1 detected by immunohistochemical staining with triple negative and non-triple negative breast carcinoma
by: Chong, Choi Yen, et al.
Published: (2019)

PEGylation of paclitaxel for inhaled chemotherapy
by: Luo, Tian
Published: (2016)

Triple negative breast cancer in Asia: An insider's view
by: Wang, C., et al.
Published: (2018)

Wnt signaling in triple-negative breast cancer
by: Pohl, S., et al.
Published: (2017)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

Investigations of bioresponsive polymers in triple negative breast cancers
by: Monteiro, Patricia
Published: (2019)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2010)

Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum and survival
by: Mukhophadyay, Asima, et al.
Published: (2012)

Combining PARP inhibition with platinum, ruthenium or gold complexes for cancer therapy
by: Yusoh, Nur Aininie, et al.
Published: (2020)

The clonal and mutational evolution spectrum of primary triple-negative breast cancers
by: Shah, S., et al.
Published: (2012)

The role of HOXA5 in triple-negative breast cancer (TNBC)
by: Mahmoud, Rinad
Published: (2021)

Integrative molecular and pathologic profiling of triple negative breast cancer
by: Alsaleem, Mansour
Published: (2021)

Recent advances in nanotheranostics for triple negative breast cancer treatment
by: Thakur, Vikram, et al.
Published: (2019)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

Potential role of targeted therapies in the treatment of triple-negative breast cancer
by: Jia, L., et al.
Published: (2016)

Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
by: Cameron, David, et al.
Published: (2013)

The current status of checkpoint inhibitors in metastatic bladder cancer
by: Fahmy Ahmed, Omar Ahmed, et al.
Published: (2016)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

The role of sodium driven bicarbonate transporters in triple negative breast cancer metastasis
by: Carroll, Christopher
Published: (2020)

A clinicopathologic study on triple-negative breast cancer patients: HUSM experience
by: Saidin, Usman Sani
Published: (2011)

Genetic determinants of TAC chemotherapy response in triple negative breast cancer patients
by: Aziz, Ahmad Aizat Abdul
Published: (2018)

Calpain system protein expression in basal-like and triple-negative invasive breast cancer
by: Storr, Sarah J., et al.
Published: (2012)

Apoptosis and cell cycle mechanisms of ampelopsin E on triple negative breast cancer cells
by: Abd Rahman, Napsiah
Published: (2017)

Potential association of nicotinamide on the telomerase activity and telomere length mediated by PARP-1 mechanism in myeloid cancer
by: Nur Rasyidah Muhammad,, et al.
Published: (2020)

Ethanol induces microglial cell death via the NOX/ROS/PARP/TRPM2 signalling pathway
by: Sha’fie, Muhammad Syahreel Azhad, et al.
Published: (2020)

Effect of combination therapy of ruthenium polypyridyl complex, [Ru(dppz)2(PIP)]2+ and parp inhibitors against several cancer cell lines
by: Yusoh, Nur Aininie
Published: (2020)

An investigation of metastatic colorectal cancer
by: Asiri, Abutaleb
Published: (2018)

Passerini multicomponent reaction: a versatile synthesis of nanomedicines for triple negative breast cancer treatment
by: Travanut, Alessandra
Published: (2021)

Mediation of triple-negative breast cancer cell fate via cellular redox and Wnt signalling
by: Pohl, Sebastian Öther-Gee
Published: (2018)

Targeted delivery of vitamin E TPGS based nanomedicine for treatment of triple negative breast cancer
by: Rajaletchumy, Veloo Kutty
Published: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nf04d8d22hes8jcm7knhuoudsc